KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Consolidated Net Income (2016 - 2025)

Boston Scientific (BSX) has disclosed Consolidated Net Income for 17 consecutive years, with $670.0 million as the latest value for Q4 2025.

  • Quarterly Consolidated Net Income rose 19.22% to $670.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 billion through Dec 2025, up 56.72% year-over-year, with the annual reading at $2.9 billion for FY2025, 56.66% up from the prior year.
  • Consolidated Net Income hit $670.0 million in Q4 2025 for Boston Scientific, down from $756.0 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $795.0 million in Q2 2025 to a low of $93.0 million in Q4 2021.
  • Historically, Consolidated Net Income has averaged $403.5 million across 5 years, with a median of $380.0 million in 2021.
  • Biggest five-year swings in Consolidated Net Income: surged 3310.0% in 2021 and later crashed 67.45% in 2022.
  • Year by year, Consolidated Net Income stood at $93.0 million in 2021, then soared by 51.61% to $141.0 million in 2022, then surged by 257.45% to $504.0 million in 2023, then grew by 11.51% to $562.0 million in 2024, then rose by 19.22% to $670.0 million in 2025.
  • Business Quant data shows Consolidated Net Income for BSX at $670.0 million in Q4 2025, $756.0 million in Q3 2025, and $795.0 million in Q2 2025.